Institute of Good Manufacturing Practices India®

Global accredited training & certification provider

IGMPI Approvals & Accreditation : Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India, Approved Training Institute of Food Safety and Standards Authority of India (FSSAI), Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India, An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh, Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC)
Trusted by organizations & training participants in over 30 countries. Training | Certification | Education | Research

Strides Pharma Warned by FDA over Uncontrolled Document Shredding

16th July 2019

Earlier this month, the USFDA warned Indian generic drugmaker Strides Pharma over good manufacturing practice (GMP) violations at its Pondicherry facility. uncontrolled shredding of documents and inadequate investigations in out-of-specification (OOS) test results were some the major violations observed by the USFDA inspectors.

The warning letter states that the investigators found rampant shredding of uncontrolled documents. Some of them were already shredded and many were awaiting shredding. Documents included batch records for US drug products and the ones which were dated just one week before the inspection began.

The FDA also said that the company did not adequately investigate OOS test results for one of its APIs and closed investigation. They even manipulated the test results testing to release the API.

The FDA wants Strides to provide an assessment of the extent of data integrity deficiencies at the facility and their potential effects on the drug quality.

On 2 July, Strides acknowledged about receiving the warning letter but said that production of six FDA approved generic drugs will not be affected. Ten abbreviated new drug applications (ANDAs) awaiting the FDA approval will get deferred till the site’s reclassification.

For further enquiries, write to or call us on: +91 8587838177, +91 8130924488, 0120-2427175, 0120-4375280

Pharmaceuticals | Food | Clinical Research | Healthcare | Medical Coding | Medical Device | Nanotechnology | IPR

Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like